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ABSTRACT
Inhaled corticosteroid therapy remains the basis for the
treatment of chronic asthma. Recent understanding of
its use includes the benefits of early introduction, and of
its plateaued dose-benefit effects. Additional beneficial
effects on asthma control and prevention of asthma
exacerbations can be obtained by combining middle-
to high-dose inhaled corticosteroid with long-acting
b -agonists and slow-release theophylline. Leukotriene
inhibitors, particularly leukotriene receptor antagonists,
are novel treatments that may also be combined with
inhaled steroid therapy. Although current asthma treat-
ments are very effective, a subgroup of asthma patients
(difficult or therapy-resistant asthma) do not respond
adequately to these treatments and need maintained
oral corticosteroid therapy. New asthma treatments
are particularly needed for this group. New treatments
for asthma include more potent topical corticosteroids
which have less potential for side-effects, inhibition
of eosinophil chemotaxis and activation such as anti-
IL-5, anti-eotaxin, eotaxin receptor antagonist, anti-VL-
A4, anti-IgE therapy, restoring Th-1/Th-2 balance either
by increasing Th-1 or reducing Th-2 T-cell activity, anti-
inflammatory cytokines such as IL-10, and specific inhi-
bitors of PDE4. These treatments may be considered
as either controllers, remitters (inducing remission of
disease), or preventors according to their modes of
action and their clinical effects. Currently, there does
not appear to be any prospect of a cure for asthma.
Key words: asthma, b -adrenergic agonists, corticos-
teroids, eosinophils, treatments.
INTRODUCTION
In order to understand the role of new treatments for
asthma, it is necessary to first review the recent changes
that have taken place and to survey the currently unmet
clinical needs for asthma so that particular areas of need
can be specifically targeted.
Over the last eight or so years since the introduction
in many countries of national asthma guidelines, there
have been several advances in the treatment of asthma.1–3
These advances relate to improved understanding of exist-
ing drugs such as the pharmacology and molecular
mechanisms of corticosteroid actions, the positioning of
the new class of long-acting b -agonists on the basis of
new studies, and the introduction of a new class of drugs
for asthma, the leukotriene inhibitors. The recognition that
chronic inflammatory processes are even present in the
airways of patients with mild asthma and that such pro-
cesses may contribute to bronchial hyperresponsiveness
and airway narrowing as well as to remodeling of the
airways has led increasingly to the use of anti-inflammatory
agents as first-line treatment of asthma, leaving the use of
short-acting b -agonists for relief of breakthrough symp-
toms. The initial recommendation has been to use either
non-steroidal ‘anti-inflammatory’ agents such as sodium
cromoglycate or nedocromil sodium, particularly in pedi-
atric asthma or low-dose inhaled corticosteroid therapy.
However, experience with these agents indicates that low-
dose inhaled steroid therapy is more predictably effective
and that the anti-inflammatory agent of choice is inhaled
corticosteroids even at low doses.4,5 There are also doubts
as to whether nedocromil sodium has anti-inflammatory
effects such as reducing eosinophil infiltration in the air-
ways submucosa.6
By contrast, more recent studies confirm the effect of
topical corticosteroid treatment in reducing the number
of inflammatory cells in the airways submucosa, such as
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eosinophils, activated T cells and mast cells, together
with the restoration of epithelial integrity.7–9 Other impor-
tant observations have also been made over the past
decade, namely the benefits of early introduction of
inhaled corticosteroid therapy, the introduction of more
potent topical steroids and the dose-response to inhaled
corticosteroids.
EARLY INTRODUCTION OF INHALED
STEROID THERAPY
Inhaled corticosteroid therapy started as early as diagnosis
is made in mild asthma has led to a greater improvement
in lung function compared with its introduction after a
delay of two years from diagnosis.10,11 Early intervention is
associated with the greatest response to steroids in terms of
lung function, symptom control and daily need for short-
acting b -agonists. Established remodeling of the airways,
which would not be easily reversed by topical steroids, has
been implicated as being the cause of the lack of reversal
of lung function following early institution of corticosteroid
therapy. Inhaled corticosteroids that are more potent than
beclomethasone dipropionate, such as fluticasone propio-
nate and budesonide, have been introduced. With fluti-
casone, patients with severe persistent asthma needing
oral corticosteroid treatment in addition to inhaled corti-
costeroids were able to discontinue oral corticosteroid
therapy with improved asthma control and FEV1.12 The
effectiveness of single versus divided daily doses of inhaled
corticosteroids has been examined, with one advantage of
single daily dosing related to improved compliance. Two
trials comparing one versus two doses per day, or four
versus two doses per day showed that more frequent
dosing yielded more effective asthma control, although the
differences in results between the two dosing regimens
were not striking.13,14
Dose–response for efficacy (measured as FEV1) achieved
a plateau at and above 1000 m g/day of budesonide.15
Poor dose–response relationship with inhaled steroid ther-
apy regarding symptom control or oral steroid-sparing
effect has been reported in other studies.16,17 Dahl et al.
have reported a dose-dependent effect of graded doses of
inhaled fluticasone (100–800 m g/day) in patients with
asthma but the mean increases in morning peak expiratory
flow rates (PEFR) observed were small, possibly because of
the chronicity of the asthma, with patients whose mean
baseline FEV1 was approximately 70% of the predicted
value.18 In this study, there was a plateau response observed
regarding the reduction in the number of exacerbations
achieved at the dose of 400 m g/day. No clear dose–
response was observed with inhaled beclomethasone and
budesonide when changes in peak expiratory flow rate were
used as the outcome measure.19,20 Clearly, if the beneficial
effects of inhaled corticosteroids plateau at a ‘middle’ dose
and if the potential systemic effects of steroids increase with
increasing inhaled dose, the smallest effective dose within
the effective dose-range should be used as maintenance
therapy.
‘ADD-ON’ THERAPY TO INHALED CORTICO-
STEROIDS WITH LONG-ACTING b -AGONIST
AND SLOW-RELEASE THEOPHYLLINE
Long-acting b -agonists were introduced in several coun-
tries at the time when there was concern regarding the
possible contribution of short-acting b -agonists to increas-
ing asthma deaths and to loss of asthma control.21,22 The
use of long-acting b -agonists in the management of
asthma has been clarified in the initial pioneering clinical
trials of salmeterol, in which salmeterol was added to
inhaled steroid therapy in patients whose asthma was not
adequately controlled at a given dose of inhaled steroids
(400 m g/day or 800 m g/day). Addition of salmeterol pro-
vided better control of asthma in terms of peak flow
measurements and day-to-day control of asthma com-
pared to the option of increasing the dose of inhaled
steroids in these short-term studies of 3 months’ dura-
tion.23,24 These studies also indicated that the dose–
response benefits from inhaled steroids do plateau at the
doses studied. More recently, the additive effects of another
long-acting b -agonist, eformoterol, to inhaled steroid
therapy (budesonide inhaled via turbohalerâ , 200 and
800 m g/day) has also been demonstrated to be persistent
for up to one year of therapy; more importantly, the addi-
tion of eformoterol to inhaled corticosteroids at either dose
provides additive protection against mild to severe attacks
of asthma.25 Long-acting b -agonists do not appear to
possess anti-inflammatory effects on their own, but the
effects observed in combination with corticosteroids may
reflect more than a bronchodilator effect, perhaps other
anti-inflammatory effects such as anti-edema effects.26 It
would be unwise to initiate long-acting b -agonist therapy
without corticosteroid therapy. A study in children showed
that salmeterol treatment alone for one year caused a
trend toward a decrease in lung function and a worsening
of bronchial hyperresponsiveness.27 Whether there are
any potentially significant differences between the two
long-acting b -agonists, salmeterol, a partial agonist, and
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eformoterol, a full agonist, is not known, but perhaps
unlikely.
Because both inhaled steroids and long-acting b -agonists
are usually administered twice daily, it would make sense to
combine both in the same inhaler. This may improve patient
compliance. These combinations should allow 2–3 different
doses of inhaled steroids with a fixed dose of long-acting
beta agonist. Such combinations will be available soon.
Addition of slow-release theophylline to inhaled corticos-
teroid therapy also provided better control of asthma than
increasing the dose of inhaled corticosteroid therapy.28 The
mechanism of action of theophylline in this response is
not clear but theophylline, particularly at the doses used
which do not achieve the so-called ‘therapeutic’ levels, has
anti-inflammatory and immunomodulatory properties.29,30
While the addition of slow-release theophylline to inhaled
steroid therapy may provide additive effects, in milder asth-
ma children inhaled corticosteroids (200 and 400 m g of
beclomethasone) were significantly more effective than
continuous theophylline treatment in optimal doses and
inhaled bronchodilators.31,32
A NEW CLASS OF ANTI-ASTHMA DRUGS:
LEUKOTRIENE INHIBITORS
A new class of drugs has been introduced over the last
couple of years in many countries around the world,
including Japan. Inhibitors of cysteinyl leukotriene synthe-
sis or leukotriene receptor antagonists such as zileuton,
zafirlukast, pranlukast and montelukast are available for
prescription, although their exact place in asthma man-
agement has not been determined in many countries.33
Regarding the development of mediator antagonists in
asthma, it is of interest to note that other mediator antago-
nists apart from leukotriene antagonists have not been
shown to be clinically effective in asthma: for instance,
platelet-activating factor, thromboxane and bradykinin
receptor antagonists. Cysteinyl-leukotrienes are important
mediators of asthma, participating in bronchoconstriction,
airway microvascular leakage and probably in eosinophil
recruitment in asthma. Leukotriene receptor antagonists
are also effective in preventing exercise-induced asthma
and allergen-induced early- and late-phase responses.34,35
When leukotriene inhibitors are administered to patients
with moderately severe asthma there is a bronchodila-
tor response as measured either by peak flow or FEV1
measurements, together with an improvement in symp-
toms and a reduction in the amount of daily b -agonist
therapy needed for controlling asthma symptoms.36–38 This
effect is observed even in patients already on inhaled
corticosteroid therapy.39,40 Such additive effects of leuko-
triene receptor antagonists can also be observed in
patients with severe asthma needing oral corticosteroid
therapy.41 Indeed, corticosteroid therapy does not appear
to modulate leukotriene metabolism. Leukotriene receptor
antagonists can be used to reduce the amount of inhaled
steroids needed to control asthma.42 Patients with aspirin-
induced asthma respond particularly well to this therapy,
as this condition is associated with increased leukotriene
production through an upregulation of the leukotriene
C4 synthase enzyme.43 These compounds can be used
as an addition to both oral or inhaled steroid therapy
to provide additional control of asthma in moderately
severe to severe asthmatics. They have been recommen-
ded by the US National Heart Lung and Blood Institution
Expert Panel Report as a first-line anti-inflammatory agent
for asthma and as an alternative to using inhaled steroid
therapy, although they are less potent than low-dose
inhaled steroids in controlling asthma. Long-term studies
are needed in this area, but the leukotriene blockers have
the advantage of being an oral therapy, which attracts
greater patient compliance.
The response to these compounds is variable and at
present there are no ways of predicting those who will
respond to the treatment. In a recent study of responses
to the 5-lipoxygenase inhibitor, zileuton, the broncho-
dilator response was related to a polymorphism of the
5-lipoxygenase gene promoter that modifies transcrip-
tion factor and the activity of the enzyme.44
UNMET CLINICAL NEEDS IN ASTHMA: TOWARDS
WHOM SHOULD NEW THERAPIES BE TARGETED?
It can be argued that the treatment for mild to moder-
ately severe asthma is effective with the use of inhaled
steroid therapy and the addition of other therapies such
as long-acting b -agonists, slow-release theophylline and
leukotriene inhibitors, and that new treatments should be
targeted towards patients whose asthma is not well
controlled by existing therapies. One approach to deter-
mining the role of new treatments in asthma would be to
look for current unmet clinical needs and target new
treatments towards these needs.
One group of patients who particularly need new effec-
tive treatments are those with ‘difficult therapy-resistant’
asthma who appear to have uncontrolled asthma des-
pite being on inhaled and often on oral corticosteroid
therapy.45,46 While much needed data should be collected
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from such patients, difficult asthma may comprise several
distinct clinical phenotypes such as brittle asthma with
recurrent and sometimes rapid onset of life-threatening
asthma exacerbations, fixed asthma with chronic obstruc-
tive component and rapid loss of lung function, and those
on high-dose oral corticosteroid therapy for control of
their asthma (corticosteroid dependent). Research on
these patients is difficult given the problem of obtaining a
sufficient number of them for a detailed study. However,
the development of protocols to define these patients
in cooperative multicenters may provide a database for
collecting such patients. The question is what are the
characteristics of these difficult asthmatics that make them
different from the asthmatic whose disease is controlled by
low to middle doses of inhaled corticosteroids alone.
A recent study of proximal mucosal airway biopsies and
of transbronchial lung biopsies from such difficult asth-
matics taking at least 20 mg of prednisolone per day
showed that these patients had a predominance of neutro-
phil influx in their proximal as well as distal airways.47
However, it is unclear whether this could have resulted
from the oral corticosteroid treatment itself. Part of the
problem is that we may not have the efficacious interven-
tions to deal with the specific inflammatory responses in
these patients.
One particular difference between the difficult and the
mild asthmatic is the difference in responsiveness to corti-
costeroids. What determines this responsiveness remains
unclear but restoring corticosteroid responsiveness could
be an important therapeutic exercise. Much has been
learnt from the rare corticosteroid-resistant asthmatic
patients who demonstrate a bronchodilator response to
b -agonists but not to two weeks’ treatment with 40 mg of
prednisolone per day.48 One proposed mechanism of
primary steroid resistance is that there is increased activa-
tion of the transcription factor activator protein-1, resulting
in binding to glucocorticoid receptors, thus preventing
the anti-inflammatory actions of steroids, either through
binding to glucocorticoid elements or through the inhi-
bition of another transcription factor, nuclear factor-k B.49
Other mechanisms of glucocorticoid down-regulation
are also possible. Down-regulation of glucocorticoid recep-
tors has been shown in circulating lymphocytes after oral
prednisolone in normal individuals,50 but it is not known
whether this occurs in the airway epithelium exposed to high
concentrations of topical steroids. Worsening of asthma
symptoms either through allergen exposure or during spon-
taneous attacks is accompanied by a decreased affinity of
the steroid receptors on circulating mononuclear cells,51,52
and patients with severe steroid-dependent asthma also
demonstrate similar reduction in receptor affinity.53 This
reduction in receptor affinity can be demonstrated by incu-
bation of mononuclear cells in vitro with the combination of
cytokines IL-2 and IL-4,54 and recent evidence indicates that
this can be prevented by an inhibitor of the intracellular
signaling p38 kinase.55 Whether these measurements are
also reflected in airway cells as a result of exposures to these
cytokines released in the airways is not known, but preven-
tion or restoration of steroid receptor affinity may provide
one way of improving the therapy of asthma.
Current treatments for corticosteroid-dependent asth-
ma include the use of immunosuppressant drugs such as
methotrexate, cyclosporin A and gold salts, which have
been demonstrated as leading to a reduction in main-
tenance steroid therapy without worsening control of
asthma.56–59 Whether these agents improve steroid recep-
tor affinity is not known. It is believed that they act on
certain T cells to inhibit activation and expression of
cytokines such as IL-5. However, no studies have been
performed which support this. Indeed, there is very little
data on the pathology of difficult asthma.
WHAT SHOULD WE BE STRIVING FOR AS IDEAL
ASTHMA TREATMENTS?
Although the term ‘anti-inflammatory treatments’ has been
applied to drugs such as corticosteroids and sodium cro-
moglycate, another term has been used that is more
relevant to the concept behind the use of such drugs,
namely ‘controllers’. Within this category, other drugs which
are not anti-inflammatory drugs are included, such as long
acting b -agonists and leukotriene inhibitors. They are con-
trollers because, when effective and taken regularly, they
control asthma. This term also implies that these drugs are
only effective so long as they are taken. Loss of control of
asthma on discontinuing inhaled steroid therapy may take a
few days to a number of weeks. With our current under-
standing of asthma mechanisms, it is unlikely that there will
be a foreseeable cure for asthma. However, approaches for
prevention and for developing drugs that may induce long
periods of disease remission should be contemplated. The
idea of disease remission was derived from cancer therapy,
whereby a protracted length of treatment with toxic cytotoxic
drugs often leads to remission of the cancer for many
months. Our current understanding of the inflammatory
process in asthma indicates that this possibility may exist.
This may also help us to determine the potential effects of
certain classes of drugs in the treatment of asthma.
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There is discussion regarding the best way of adminis-
tering anti-asthma drugs, whether by the oral or inhaled
route. While emphasis, to date, has been placed on
the inhaled route, due to the use of corticosteroids and
b -adrenergic agonists, it is believed that oral therapy
may be better because of its simplicity and also because
of greater patient adherence to such therapy. However,
whether either is used is very dependent upon the best
route of administration for that drug. Corticosteroids are
best administered by the inhaled route with the maximal
benefit/side-effect ratio and are most effective when
delivered as such. Other drugs, such as leukotriene inhi-
bitors, are not as effective when administered by the
inhaled route and have acceptable side-effect profiles by
the oral route. Although patients may be more compliant
with oral administration, it is to be noted that patient
adherence may be low with such therapies, as noted with
antihypertensive therapy. There may well be advantages
to using the oral route in certain patient subgroups, such
as the very young and the elderly, who may have difficul-
ties with self-administration of inhaled drugs. With either
route, however, clinicians will still have to address the
problem of adherence to treatment.
Many new inhaler devices have been introduced
recently, including the CFC-free metered dose inhalers,
multidose powder devices, inhalers triggered by inspira-
tory flow, new spacer devices, portable nebulizers etc.
While the purpose of these new devices is to combine
user friendliness with greater lower airway deposition
characteristics, this plethora of devices may become
confusing for both the doctor and the patient. There may
be some requirement to control the introduction of dif-
ferent types of devices and to provide some uniformity.
The new non-CFC metered dose inhalers are able to
produce finer particles that penetrate deeper into the air-
ways.60 Whether this is an advantage to the obstructed
asthmatic is unclear.
RECENT NEW APPROACHES TO THE THERAPY
OF ASTHMA
Although there are specific areas of unmet clinical needs
in asthma, research into new drugs for asthma has not
necessarily focused on these areas. Often new treatments
with potentially important side-effects have been reserved
for patients with difficult severe asthma. The past 10 years
have seen much research into the development of receptor
antagonists such as leukotriene, platelet-activating factor
and bradykinin B2-receptor antagonists. Only leukotriene
antagonists have been shown to have beneficial effects.
Phosphodiesterase 4 (PDE4) is the predominant phospho-
diesterase in inflammatory cells, including mast cells,
eosinophils, T-lymphocytes, macrophages and epithelial
cells. Inhibitors of PDE4 have been the subject of recent
clinical trials although to date no full analysis has been
published.
STRATEGIES FOR INHIBITION OF EOSINOPHIL
ACTIVATION AND RECRUITMENT
Eosinophils have long been implicated in the pathogenesis
of asthma, being present in the airways submucosa with
evidence of activation as indicated by the presence of
release of eosinophil proteins such as eosinophil cationic
protein and major basic protein. Eosinophils are also
important sources of cysteinyl-leukotrienes. Much has
been learnt about the kinetics of eosinophil traffic between
the bone marrow and the airways. Eosinophilopoiesis in
the bone marrow is under the control of IL-5, which regu-
lates terminal differentiation of these cells.61 Release of
chemokines such as eotaxin in the airways may be the
event that causes chemo-attraction of eosinophils to the
airways, through the upregulation of adhesion molecules
such as ICAM-1 and VCAM-1 on the vascular endothe-
lium and the integrins VLA4 on the eosinophil.62 There-
fore, several strategies for inhibiting eosinophil activation
and recruitment have been put into place. These include
inhibition of IL-5 effects by using a neutralizing antibody
or an IL-5 receptor antagonist; inhibition of chemokine
effects through an antagonist or antibody to chemokine
receptor CCR3; and blocking the effects of adhesion
molecules with an anti-ICAM-1 or anti-VLA4 antibody.
Studies in animal models indicate that anti-IL-5 antibodies
can inhibit eosinophil influx into the airways of sensitized
guinea-pigs or monkeys following allergen exposure and
can also inhibit the increase in bronchial hyperresponsive-
ness.63–65 In one study, the effect of a single administra-
tion of anti-IL-5 antibody provided protection for up to
3 months, suggesting that a state of remission may have
been obtained. An anti-VLA4 antibody inhibited bronchial
hyperresponsiveness but not the eosinophil influx.66
This treatment could be used to reverse established
disease and could be tried in patients with severe asthma,
in particular. The idea of inducing remission of disease
would also be an exciting prospect. It could also be
administered as a prophylaxis for asthma. Inherent in this
approach is the idea that inhibiting a single target may
be sufficient. However, studies in animals indicate that
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IL-5 and chemokines such as regulated on activation,
normal T-cells expressed (RANTES) and eotaxin cooperate
in eosinophil recruitment and activation.67,68 This suggests
that a combined inhibition of IL-5 and chemokine effects
may be more effective.
MODULATION OF TH-1/TH2 T-CELL ACTIVATION
The concept of interfering with the imbalance of the Th-1
and Th-2 T cell activities derives from the observations
that Th-2 derived cytokines such as IL-4 and IL-5 are
over-expressed in asthma, and that Th-2 T cells may be
suppressed by enhancing Th-1 responses. Cytokines from
Th-1 cells, notably IFNg and IL-12, can prevent or reverse
Th-2 responses. There is an inverse association between
a positive tuberculin test indicating a Th-1-mediated
response and the development of atopy.69 Apart from inhi-
biting the Th-2 response, it would be possible to enhance
Th-1 T-cell function. Interleukin-12 and IFNg are both
potential candidates for use as treatment in asthma, and
can inhibit allergic eosinophilia and bronchial hyper-
responsiveness in the ovalbumin-sensitized mouse.70–73 A
reduction in IL-12 expression in airway biopsies of patients
with allergic asthma has been reported, supporting a
reduction in Th-1 response.74 Other approaches would
include the use of vaccination to induce a Th-1 response.
Approaches aimed at restoring the Th-1/Th-2 imbalance
(e.g. Bacille Calmette-Guerin (BCG) vaccination) may be
used early in the disease process, and perhaps targeted
towards those at risk of developing asthma. However,
ways of identifying such people at risk are needed.
More classical immunomodulators such as cyclosporin
A have been tried in asthma and found to possess oral
steroid-sparing effects in severe asthma.58 It is likely that
such T cell inhibitors inhibit both Th-1 and Th-2 cells and,
therefore, do not reset the imbalance in T-helper subsets.
The mechanisms by which Th-2 cells are selectively acti-
vated involve the costimulatory molecule B7.2, which is
expressed on antigen-presenting cells that interact with
CD28 on T cells.75 Blocking this costimulatory molecule
may yield novel therapies.
TARGETING IGE RECEPTORS WITH AN
ANTI-IGE APPROACH
IgE is an important mediator of allergic airways disease
and a relationship between IgE levels and airway hyper-
responsiveness, and between IgE levels and asthma
symptoms has been reported.76,77 Allergen exposure of
sensitized asthmatics may cause both early and late
bronchoconstrictor responses which are considered to
be both IgE and mast cell dependent. The late response
is associated with airway inflammation characterized
by eosinophil influx, airway edema and activation of
adhesion molecules.
A recombinant humanized monoclonal antibody that
binds to IgE recognized by the high-affinity IgE receptor
Fce R1 has been developed. This antibody blocks the bind-
ing of IgE to mast cells and inhibits mediator release.78
This antibody (rhuMAb-E25) reduces free IgE levels in
serum,79 and inhibits both the early and late responses to
allergen exposure.80,81 Which categories of patients should
such a potential treatment be targeting? From its proper-
ties, this novel approach should be more preventive
(similar to the use for sodium cromoglycate). For example,
it could be used as prophylaxis for seasonal rhinitis or
asthma, or for preventing the onset of symptoms in aller-
gic patients. In the latter group, however, we have no
diagnostic methods for predicting allergic patients at risk
of developing asthma. This approach is now being tested
in symptomatic patients with allergic asthma.
Another approach to inhibiting mast cell activation
is the use of heparin, which may act by inhibiting IP3-
mediated calcium release. Inhaled heparin has been
shown to protect against exercise-induced asthma82 and
attenuate allergen-induced early and late responses.83
The anti-allergic effect of heparin was found to be within
the nonanticoagulant fraction.84
ANTI-INFLAMMATORY CYTOKINES AND
INHIBITION OF PRO-INFLAMMATORY CYTOKINES
A number of cytokines expressed in asthma appear to
have anti-inflammatory properties, for example inter-
leukin-10 (IL-10) and interleukin-1 receptor antagonist
(IL-1ra). IL-10, which is produced by CD4+ and CD8+
T cells and activated monocytes, is a potent inhibitor of
monocyte/macrophage function, of IL-4 and IL-5 pro-
duction by Th2 T cells, of eosinophil survival and of
IL-4 induced IgE synthesis. There is a reduced capacity
for alveolar macrophages to produce IL-10 in asthma, a
defect which is reversed by inhaled corticosteroid ther-
apy.85 IL-10 inhibits eosinophilia induced by ovalbumin in
immunized mice.86,87 IL-10 has been administered to
normal volunteers inducing a fall in circulating T cells with
suppression of T-cell proliferation and a reduction of
TNFa and IL-1b production by mononuclear cells.88
IL-1ra can block the proliferation of Th-2 cell clones but
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not of Th-1 cell clones,89 and in the ovalbumin-sensitized
model, there is an inhibition of allergen-induced bronchial
hyperreactivity and pulmonary eosinophilia.90 Other
approaches include the inhibition of effects of pro-
inflammatory cytokines such as TNFa and IL-1b, which
may be overexpressed in chronic severe asthma. These
cytokines may play a role as amplifying mechanisms,
through the activation of NF-k B and other transcription
factors. Blocking antibodies may be used or soluble TNF
receptors or IL-1ra. These approaches should probably be
directed towards established diseases, particularly those
which do not respond to currently available therapies.
POTENTIAL FOR NEW CORTICOSTEROIDS
While currently available inhaled corticosteroids are highly
effective and have a good margin of safety, there is still
room for improvements. Development of even more potent
corticosteroids with lesser potential for systemic side-effects
continues. However, this raises several issues as to whether
more potent steroids will provide more clinical benefits,
particularly for the more difficult asthmatic patients. In
addition, some contribution of systemic effects of inhaled
corticosteroids in suppressing eosinophilopoiesis in the
bone marrow has been raised. The potential prolongation
of effects of topical steroids delivered by liposomes in the
airways may be useful. These improvements may lead to
the use of a once daily inhaled steroid dosage.
Corticosteroids may control airway inflammation
through suppression of transcription factors largely
through a direct interaction of the activated glucocorti-
coid receptor with transcription factors such as AP-1 and
NFk B (trans-repression).91 It seems likely that the side-
effects of corticosteroids are mostly the result of trans-
activation of genes through binding of glucocorticoid
receptors to DNA. Some steroids may have greater
potency against trans-repression than trans-activation,92
which may translate into less side-effect profile, while
increasing anti-inflammatory potency. Other approaches
would be to develop specific transcription factor blockers.
CONCLUSIONS
Although there have been new advances in the treatment
of asthma, the search for new targets to aim at in the
hope of developing novel asthma treatments continues
as long as research into the inflammatory and immuno-
logical mechanisms of asthma progresses. However, this
search must be combined with the clinical needs of
patients with asthma, and of the particular needs of
certain subgroups. It should be on the basis of their
properties that novel drugs be considered for use as pre-
ventors, inducers of remission, controllers or relievers.
The long-term aim of any new asthma treatment is to
prevent the disease from occurring, which means target-
ing susceptible persons, and to provide better controllers
or drugs that cause remission in those at the more severe
spectrum of the disease. Current treatments for asthma
are very effective for those with mild to moderate disease
severity.
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